Avidity Partners Management LP Caribou Biosciences, Inc. Transaction History

Avidity Partners Management LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$4.82 - $8.26 $2.77 Million - $4.75 Million	-574,860 Reduced 9.04%	5,785,352 $29.7 Million
Q4 2023 Feb 14, 2024	BUY	$3.58 - $6.25 $1.11 Million - $1.94 Million	310,000 Added 5.12%	6,360,212 $36.4 Million
Q3 2023 Nov 14, 2023	BUY	$4.08 - $8.14 $13.4 Million - $26.8 Million	3,291,612 Added 119.32%	6,050,212 $28.9 Million
Q1 2023 May 15, 2023	SELL	$4.3 - $7.78 $533,200 - $964,720	-124,000 Reduced 4.3%	2,758,600 $14.6 Million
Q4 2022 Feb 14, 2023	SELL	$5.57 - $11.01 $1.62 Million - $3.19 Million	-290,000 Reduced 9.14%	2,882,600 $18.1 Million
Q3 2022 Nov 14, 2022	BUY	$5.34 - $12.79 $1.19 Million - $2.85 Million	222,600 Added 7.55%	3,172,600 $33.5 Million
Q2 2022 Aug 15, 2022	BUY	$5.1 - $9.74 $667,758 - $1.28 Million	130,933 Added 4.64%	2,950,000 $16 Million
Q1 2022 May 16, 2022	BUY	$8.42 - $15.32 $1.22 Million - $2.22 Million	145,000 Added 5.42%	2,819,067 $25.9 Million
Q4 2021 Feb 14, 2022	BUY	$14.59 - $23.26 $2.92 Million - $4.65 Million	200,000 Added 8.08%	2,674,067 $40.4 Million
Q3 2021 Nov 15, 2021	BUY	$15.75 - $30.29 $39 Million - $74.9 Million	2,474,067 New	2,474,067 $59.1 Million

135

52.6M

148K

70.7K

Ticker CRBU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,840,800
Market Cap $110M
Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

Stay updated on Avidity Partners Management LP with notifications on news.